ADARx Pharmaceuticals priced its $446.3 million IPO, adding to 2026’s rapid biotech public-market pace. The RNAi specialist sold 26.25 million shares at $17 apiece and began trading on Nasdaq under the ticker ADRX. The company is advancing onvuzosiran for hereditary angioedema in Phase 3, while other RNAi candidates—including agazisiran for kidney diseases, geographic atrophy, and paroxysmal nocturnal hemoglobinuria—sit across mid-stage programs. ADARx also received a boost via a private stock sale to partner AbbVie. The listing underscores sustained investor appetite for RNA platforms that can expand beyond liver delivery and potentially serve chronic, systemic targets if efficacy and dosing durability hold up in later-stage studies.